Drugs / CD34+ cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04925687 | Jun 2021 → Nov 2023 | retinitis pigmentosa | University of California, Davis | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34+ cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04925687 ↗ |
| Modality | Cell therapy | “autologous CD34+ stem cells” NCT04925687 ↗ |
| Route | Intravitreal | “administered intravitreal injection” NCT04925687 ↗ |